Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Acacia Pharma Group plc: PDMR DEALING/EXERCISE OF SHARE OPTIONS

Acacia Pharma Group plc
Posted on: 03 Jul 18

Cambridge, UK and Indianapolis, US - 3 July 2018:  Acacia Pharma Group plc ( the "Company), (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea and vomiting treatments for surgical and cancer patients, announces that it has received notice of exercise of options under the Company's Enterprise Management Incentive Share Option Plan from Dr Gabriel Fox (Chief Medical Officer and PDMR) to subscribe for 200,000 Ordinary Shares of £0.02 each in the Company (the "New Ordinary Shares") at an exercise price of £0.19 each.
                           
Following the exercise of these options, Dr Fox holds 252,704 Ordinary Shares, representing approximately 0.47% of the Company's enlarged issued share capital. 

Application has been made to Euronext Brussels for the admission of the New Ordinary Shares to trading on Euronext Brussels ("Admission") and Admission will occur on 3 July 2018.  The New Ordinary Shares will rank pari passu in all respects with the Company's existing Ordinary Shares in issue.
                                    
Following issue of the New Ordinary Shares, the Company's total issued share capital will consist of 53,119,061 Ordinary Shares with one voting right per share. The Company does not hold any Ordinary Shares in Treasury. Therefore, following the issue of the New Ordinary Shares, the total number of voting rights in the Company is 53,119,061.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:

1 Details of the person discharging managerial responsibilities/person closely associated
a)NameDr Gabriel Fox
2 Reason for the notification
a)Position/status Chief Medical Officer/PDMR
b)Initial notification/ Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameAcacia Pharma Group plc 
b)LEI213800SLDKXWKT6E3381
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument

 

Identification code 
Ordinary Shares of £0.02 each

 

 

 

GB00BYWF9Y76
b)Nature of the transactionShare options exercise 
c)Price(s) and volume(s)200,000 Ordinary Shares at a price of £0.02 pence per share
d) Aggregated information
- Aggregated volume
- Price

 
N/A
e)Date of the transaction  2 July 2018

 
f)Place of the transactionEuronext Brussels (XBRU)

Contacts 

Acacia Pharma Group plc
Julian Gilbert, CEO
Christine Soden, CFO
+44 1223 919760
Citigate Dewe Rogerson 
Mark Swallow, Shabnam Bashir, David Dible
+44 20 7638 9571

 


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Acacia Pharma Group plc via GlobeNewswire
HUG#2202863
GlobeNewswire
globenewswire.com

Last updated on: 04/07/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.